Inhibition of monoamine oxidases and neuroprotective effects: chalcones vs. chromones-Reference-Cited by-同舟云学术

Inhibition of monoamine oxidases and neuroprotective effects: chalcones vs. chromones

Published:2024-08-15 Issue: Volume: Page:
ISSN:1381-1991
Container-title:Molecular Diversity
language:en
Short-container-title:Mol Divers

Author:

Ipe Reshma,Oh Jong Min,Kumar Sunil,Ahmad Iqrar,Nath Lekshmi R.,Bindra Sandeep,Patel Harun,Kolachi Krishna Yallappa,Prabhakaran Prabitha,Gahtori Prashant,Syed Asad,Elgorbanh Abdallah M.,Kim Hoon,Mathew Bijo

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11030-024-10959-w.pdf

Reference66 articles.

1. Zheng J, Zhang X, Zhen X (2019) Development of adenosine A2A receptor antagonists for the treatment of Parkinson’s Disease: a recent update and challenge. ACS Chem Neurosci 10:783–791. https://doi.org/10.1021/acschemneuro.8b00313

2. Dorsey ER, Elbaz A, Nichols E, Abbasi N, Abd-Allah F, Abdelalim A, Adsuar JC, Ansha MG, Brayne C, Choi J-YJ et al (2018) Global, regional, and National Burden of Parkinson’s Disease, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol 17:939–953. https://doi.org/10.1016/S1474-4422(18)30295-3

3. Spires-Jones TL, Attems J, Thal DR (2017) Interactions of pathological proteins in neurodegenerative diseases. Acta Neuropathol 134:187–205. https://doi.org/10.1007/s00401-017-1709-7

4. Priyadarshi A, Khuder SA, Schaub EA, Priyadarshi SS (2001) Environmental risk factors and Parkinson’s Disease: a metaanalysis. Environ Res 86:122–127. https://doi.org/10.1006/enrs.2001.4264

5. de Lau LM, Breteler MM (2006) Epidemiology of Parkinson’s Disease. Lancet Neurol 5:525–535. https://doi.org/10.1016/S1474-4422(06)70471-9